Immunologic Factor
alemtuzumab
[ a-lem-too-zoo-mab ]
Brand Names:
Campath; Lemtrada
Effect:
Increased Lymphocyte Cell Destruction
May Treat:
Leukemia, Lymphocytic, Chronic, B-Cell
More Information:
Definitions related to alemtuzumab:
-
A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. (NCI04)NCI ThesaurusU.S. National Cancer Institute, 2021
-
A type of monoclonal antibody used in the treatment of leukemia. Monoclonal antibodies are laboratory-produced substances that can locate and bind to cancer cells.NCI Dictionary of Cancer TermsU.S. National Cancer Institute, 2021
-
An anti-CD52 ANTIGEN monoclonal antibody used for the treatment of certain types of CD52-positive lymphomas (e.g., CHRONIC LYMPHOCYTIC LEUKEMIA; CUTANEOUS T-CELL LYMPHOMA; and T-CELL LYMPHOMA). Its mode of actions include ANTIBODY-DEPENDENT CELL CYTOTOXICITY.NLM Medical Subject HeadingsU.S. National Library of Medicine, 2021
-
(anti-cd52 monoclonal antibody) Any monoclonal antibody directed against the cell surface glycoprotein CD52, regardless of the antibody type (e.g., rat, mouse, humanized).NCI ThesaurusU.S. National Cancer Institute, 2021
Return to OpenMD Medical Dictionary
> A
This content should not be used in place of medically-reviewed decision support reference material or professional medical advice. Some terms may have alternate or updated definitions not reflected in this set. The definitions on this page should not be considered complete or up to date.